Lutris Pharma News
10 articles
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...
Lutris Pharma, a clinical-stage biopharmaceutical company, has announced the results of its phase 2 clinical trial for LUT014 gel, a topical B-Raf inhibitor. The trial, which is double-blind and placebo-controlled, aims to address acneiform rash toxicities in patients undergoing EGFR inhibitor therapy. The results will be presented at the ESMO Gastrointestinal Cancers Congress 2025. LUT014 leverages the paradoxical effect of B-Raf inhibitors to enhance cell proliferation and mitigate adverse dermatological effects associated with cancer therapies. The company focuses on improving the effectiveness and quality of life for patients treated with EGFR inhibitors or radiation, where dermal toxicity often reduces therapy compliance.
Product StageFDA approved/pending approval
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...
Lutris Pharma, a clinical-stage biopharmaceutical company, announced positive results from its phase 2 clinical trial of LUT014 gel, a novel B-Raf inhibitor. The gel demonstrated significant reductions in acneiform rash in patients undergoing EGFR inhibitor therapy, a common issue that can lead to reduced cancer treatment efficacy. The trial results were presented at the AACR Annual Meeting 2025, highlighting the potential of LUT014 as a therapeutic option. The company also completed a $30 million financing round in January 2025, supporting further clinical development. The trial involved 118 colorectal cancer patients, showing promising success rates in both intention-to-treat and per-protocol analyses.
Product StageInvestment
Lutris Pharma, a Tel Aviv, Israel-based clinical stage biopharmaceutical company, raised $30M in funding
Lutris Pharma, a clinical stage biopharmaceutical company based in Tel Aviv, has raised $30 million in funding. The investment round was led by Columbus Venture Partners and Pontifax Venture Capital, with participation from Peregrine Ventures and aMoon Fund. The funds will be used to advance the development of LUT014, a topical gel designed to reduce rashes caused by EGFR inhibitors, a common side effect of cancer therapies. The company, led by CEO Noa Shelach, focuses on improving the effectiveness and quality of life for patients undergoing anti-cancer treatments. LUT014 has completed phase 2 clinical trials for colorectal cancer and phase 1/2 trials for radiation-induced dermatitis.
Investment
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...
Lutris Pharma, a clinical-stage biopharmaceutical company, has completed enrollment for its phase 2 trial of LUT014, a topical B-Raf inhibitor, aimed at treating acneiform rash in metastatic colorectal cancer patients undergoing EGFR inhibitor therapy. The trial, involving 117 subjects across 20 international sites, seeks to evaluate the efficacy and safety of LUT014. The primary endpoint is to achieve treatment success by reducing the severity of acneiform lesions. The company anticipates reporting topline results in Q1 2025. This development is significant as EGFR inhibitors, while effective, often cause skin toxicities that impact patient quality of life and treatment adherence. LUT014 aims to mitigate these side effects, potentially enhancing cancer therapy effectiveness. The trials completion marks a critical milestone for Lutris Pharma, with expectations of presenting results at a major medical meeting.
Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting
Lutris Pharma presented data on skin toxicity from EGFR inhibitors at the 2023 American Academy of Dermatology Annual Meeting. The analysis confirmed that a significant percentage of cancer patients treated with EGFR inhibitors develop a serious rash, highlighting an unmet medical need. Preliminary results from Lutris Pharmas phase 2 trial of their lead compound, LUT014, showed promising results in treating acneiform lesions caused by EGFR inhibitor therapy. Lutris Pharma aims to provide novel topical therapies to mitigate the side effects of anti-cancer treatments. The companys lead asset, LUT014, is currently in a phase 2 clinical trial for metastatic colorectal cancer patients.
Customers
Lutris Pharma to Present at the 16th Annual European Life Sciences CEO Forum in March
Lutris Pharma, a clinical stage biopharmaceutical company, will present a company overview at the 16th Annual European Life Sciences CEO Forum. The company will also host virtual one-on-one meetings with investors. Lutris Pharma focuses on improving anti-cancer therapies and reducing side effects. Their lead asset, LUT014, is a topical B-Raf Inhibitor currently in a phase 2 clinical trial. For more information, visit www.lutris-pharma.com.
Investment
Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing
Lutris Pharma has been awarded a $5.0 million grant by the California Institute of Regenerative Medicine (CIRM) for the further development of LUT017 gel, a novel inhibitor of BRAF, for skin regeneration and wound healing. The grant will be used for manufacturing the drug product, evaluating its stability and efficacy, and completing the IND submission for a phase 1 clinical trial. The CEO of Lutris Pharma expressed the importance of this funding in expanding their product pipeline to non-oncological indications and providing a therapeutic option for patients with venous leg ulcers. LUT017 is a topical B-Raf inhibitor that stimulates the growth of skin stem cells to accelerate wound healing.
Investment
Lutris Pharma radiation trial brings positive results for breast cancer patients
Lutris Pharma, an Israel-based biopharma company, has announced positive results from its clinical trial treating breast cancer patients with radiation dermatitis (RD) using its lead compound, LUT014. The trial showed that 75% of the eight patients who developed grade 2 RD had complete resolution, improving to grade 0 dermatitis. All patients reported an improvement in quality of life by day 28. The companys CEO, Noa Shelach, expressed optimism about the results and the potential of LUT014 to treat this patient population.
Customers
Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., Ph.D., as Chairman of the Board of Directors
Lutris Pharma has appointed Antoni Ribas as Chairman of the Board of Directors. Dr. Ribas, the founder of Lutris Pharma, has been a director of the company since its inception. The appointment is expected to have a positive impact on the companys growth. Dr. Ribas is known for his contributions to the discovery and development of new and effective treatments for malignant melanoma. Lutris Pharmas lead program, LUT014, is a topical B-Raf inhibitor currently in clinical trials for patients with metastatic colorectal cancer treated with EGFR inhibitors and for the treatment of radiation-induced dermatitis in breast cancer patients. The company aims to improve anti-cancer therapy effectiveness and quality of life for patients by reducing dose-limiting side effects.
Management Changes
Cancer-fighting therapy shows promise as treatment to speed up wound healing
UCLA researchers have found that a type of targeted therapy used to treat advanced melanoma could potentially accelerate the healing of acute and chronic wounds. The therapy, known as BRAF inhibitors, blocks a mutated gene in melanoma and can trigger a cellular cascade that accelerates wound healing. The researchers conducted experiments using the BRAF inhibitor drug vemurafenib and found that it promoted faster healing of cutaneous wounds. The findings have the potential to benefit various areas of medicine, including post-surgery recovery and reducing skin-related side effects of cancer treatments. The researchers plan to further study the mechanisms and conduct clinical studies of potential topical BRAF treatments in the future.
Customers
